{"transactions":[{"id":694319,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2026-08-06T20:13:19.000Z","date":"2026-08-04","kind":"sale","planned":true,"acquired":false,"shares":30000,"price":30.48,"value":914400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $30.25 to $30.88. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":54645,"source":{"system":"sec-edgar","filing":"0001439222-26-000120","document":"wk-form4_1786047196.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922226000120/wk-form4_1786047196.xml","form_type":"4"}},{"id":718399,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-02T20:15:17.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":32341,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer."}],"balance_after":32341,"derivative":{"exercise_price":18.48,"expiration_date":"2036-07-01","underlying":"Common Stock","underlying_shares":32341},"source":{"system":"sec-edgar","filing":"0001193125-26-294552","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000119312526294552/ownership.xml","form_type":"4"}},{"id":718398,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted stock units","published_at":"2026-07-02T20:03:16.000Z","date":"2026-07-01","kind":"exercise","planned":true,"acquired":false,"shares":8375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on July 1, 2023. Beginning on July 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on July 1, 2023. Beginning on July 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":8375},"source":{"system":"sec-edgar","filing":"0001439222-26-000110","document":"wk-form4_1783022592.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922226000110/wk-form4_1783022592.xml","form_type":"4"}},{"id":718397,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2026-07-02T20:03:16.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":4007,"price":37.56,"value":150502.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted stock units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated July 1, 2023."}],"balance_after":84645,"source":{"system":"sec-edgar","filing":"0001439222-26-000110","document":"wk-form4_1783022592.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922226000110/wk-form4_1783022592.xml","form_type":"4"}},{"id":718396,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2026-07-02T20:03:16.000Z","date":"2026-07-01","kind":"exercise","planned":true,"acquired":true,"shares":8375,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":88652,"source":{"system":"sec-edgar","filing":"0001439222-26-000110","document":"wk-form4_1783022592.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922226000110/wk-form4_1783022592.xml","form_type":"4"}},{"id":729278,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted stock units","published_at":"2026-06-23T21:15:51.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service."}],"balance_after":3000,"derivative":{"underlying":"Common stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001439222-26-000085","document":"wk-form4_1782249348.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922226000085/wk-form4_1782249348.xml","form_type":"4"}},{"id":729277,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Performance share units","published_at":"2026-06-23T21:15:51.000Z","date":"2026-06-18","kind":"exercise","planned":false,"acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service."}],"balance_after":9000,"derivative":{"underlying":"Common stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001439222-26-000085","document":"wk-form4_1782249348.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922226000085/wk-form4_1782249348.xml","form_type":"4"}},{"id":814541,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Performance share units","published_at":"2026-04-06T20:10:02.000Z","date":"2026-04-02","kind":"exercise","planned":true,"acquired":false,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each performance share unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The PSUs were granted on March 1, 2024. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified regulatory milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified commercial milestone. The performance criteria for the specified regulatory milestone was determined to have been met on April 2, 2026, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The PSUs were granted on March 1, 2024. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified regulatory milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified commercial milestone. The performance criteria for the specified regulatory milestone was determined to have been met on April 2, 2026, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":8500,"derivative":{"underlying":"Common stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001439222-26-000065","document":"wk-form4_1775506198.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922226000065/wk-form4_1775506198.xml","form_type":"4"}},{"id":814540,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2026-04-06T20:10:02.000Z","date":"2026-04-02","kind":"sale","planned":true,"acquired":false,"shares":2940,"price":34.71,"value":102047.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's performance share unit agreement dated March 1, 2024."}],"balance_after":80277,"source":{"system":"sec-edgar","filing":"0001439222-26-000065","document":"wk-form4_1775506198.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922226000065/wk-form4_1775506198.xml","form_type":"4"}},{"id":814539,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2026-04-06T20:10:02.000Z","date":"2026-04-02","kind":"exercise","planned":true,"acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 311 shares purchased through the Company's employee stock purchase plan."}],"balance_after":83217,"source":{"system":"sec-edgar","filing":"0001439222-26-000065","document":"wk-form4_1775506198.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922226000065/wk-form4_1775506198.xml","form_type":"4"}},{"id":868261,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted stock units","published_at":"2026-03-03T21:15:58.000Z","date":"2026-03-02","kind":"exercise","planned":true,"acquired":false,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The restricted stock units were granted on March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The restricted stock units were granted on March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":8000,"derivative":{"underlying":"Common stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001439222-26-000040","document":"wk-form4_1772572555.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922226000040/wk-form4_1772572555.xml","form_type":"4"}},{"id":868260,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted stock units","published_at":"2026-03-03T21:15:58.000Z","date":"2026-03-02","kind":"exercise","planned":true,"acquired":false,"shares":5666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":5667,"derivative":{"underlying":"Common stock","underlying_shares":5666},"source":{"system":"sec-edgar","filing":"0001439222-26-000040","document":"wk-form4_1772572555.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922226000040/wk-form4_1772572555.xml","form_type":"4"}},{"id":868259,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted stock units","published_at":"2026-03-03T21:15:58.000Z","date":"2026-03-02","kind":"exercise","planned":true,"acquired":false,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001439222-26-000040","document":"wk-form4_1772572555.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922226000040/wk-form4_1772572555.xml","form_type":"4"}},{"id":868258,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock options (right to buy)","published_at":"2026-03-03T21:15:58.000Z","date":"2026-03-01","kind":"grant","planned":true,"acquired":true,"shares":52000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on March 1, 2026. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":52000,"derivative":{"exercise_price":30.23,"expiration_date":"2036-03-01","underlying":"Common stock","underlying_shares":52000},"source":{"system":"sec-edgar","filing":"0001439222-26-000040","document":"wk-form4_1772572555.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922226000040/wk-form4_1772572555.xml","form_type":"4"}},{"id":868257,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted stock units","published_at":"2026-03-03T21:15:58.000Z","date":"2026-03-01","kind":"grant","planned":true,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The restricted stock units were granted on March 1, 2026. Beginning on March 1, 2027, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The restricted stock units were granted on March 1, 2026. Beginning on March 1, 2027, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":22000,"derivative":{"underlying":"Common stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001439222-26-000040","document":"wk-form4_1772572555.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922226000040/wk-form4_1772572555.xml","form_type":"4"}},{"id":868256,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted stock units","published_at":"2026-03-03T21:15:58.000Z","date":"2026-03-01","kind":"grant","planned":true,"acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The restricted stock units were granted on March 1, 2026. Beginning on March 1, 2027, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The restricted stock units were granted on March 1, 2026. Beginning on March 1, 2027, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":14000,"derivative":{"underlying":"Common stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001439222-26-000040","document":"wk-form4_1772572555.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922226000040/wk-form4_1772572555.xml","form_type":"4"}},{"id":868255,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2026-03-03T21:15:58.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":1187,"price":28.96,"value":34375.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2025."}],"balance_after":74406,"source":{"system":"sec-edgar","filing":"0001439222-26-000040","document":"wk-form4_1772572555.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922226000040/wk-form4_1772572555.xml","form_type":"4"}},{"id":868254,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2026-03-03T21:15:58.000Z","date":"2026-03-02","kind":"exercise","planned":true,"acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":75593,"source":{"system":"sec-edgar","filing":"0001439222-26-000040","document":"wk-form4_1772572555.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922226000040/wk-form4_1772572555.xml","form_type":"4"}},{"id":868253,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2026-03-03T21:15:58.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":1681,"price":28.96,"value":48681.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2024."}],"balance_after":71593,"source":{"system":"sec-edgar","filing":"0001439222-26-000040","document":"wk-form4_1772572555.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922226000040/wk-form4_1772572555.xml","form_type":"4"}},{"id":868252,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2026-03-03T21:15:58.000Z","date":"2026-03-02","kind":"exercise","planned":true,"acquired":true,"shares":5666,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":73274,"source":{"system":"sec-edgar","filing":"0001439222-26-000040","document":"wk-form4_1772572555.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922226000040/wk-form4_1772572555.xml","form_type":"4"}},{"id":868251,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2026-03-03T21:15:58.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":1187,"price":28.96,"value":34375.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2023."}],"balance_after":67608,"source":{"system":"sec-edgar","filing":"0001439222-26-000040","document":"wk-form4_1772572555.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922226000040/wk-form4_1772572555.xml","form_type":"4"}},{"id":868250,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2026-03-03T21:15:58.000Z","date":"2026-03-02","kind":"exercise","planned":true,"acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":68795,"source":{"system":"sec-edgar","filing":"0001439222-26-000040","document":"wk-form4_1772572555.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922226000040/wk-form4_1772572555.xml","form_type":"4"}},{"id":955329,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Performance share units","published_at":"2026-01-03T01:15:43.000Z","date":"2025-12-30","kind":"exercise","planned":true,"acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each performance share unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The PSUs were granted on March 1, 2023. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified research milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified regulatory milestone. The performance criteria for the specified regulatory milestone was determined to have been met on December 29, 2025, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The PSUs were granted on March 1, 2023. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified research milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified regulatory milestone. The performance criteria for the specified regulatory milestone was determined to have been met on December 29, 2025, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001439222-26-000006","document":"wk-form4_1767402940.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922226000006/wk-form4_1767402940.xml","form_type":"4"}},{"id":955328,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2026-01-03T01:15:43.000Z","date":"2025-12-30","kind":"sale","planned":true,"acquired":false,"shares":2932,"price":27.09,"value":79427.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's performance share unit agreement dated March 1, 2023."}],"balance_after":64795,"source":{"system":"sec-edgar","filing":"0001439222-26-000006","document":"wk-form4_1767402940.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922226000006/wk-form4_1767402940.xml","form_type":"4"}},{"id":955327,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2026-01-03T01:15:43.000Z","date":"2025-12-30","kind":"exercise","planned":true,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":67727,"source":{"system":"sec-edgar","filing":"0001439222-26-000006","document":"wk-form4_1767402940.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922226000006/wk-form4_1767402940.xml","form_type":"4"}},{"id":1000432,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock options (right to buy)","published_at":"2025-11-13T21:08:59.000Z","date":"2025-11-11","kind":"exercise","planned":true,"acquired":false,"shares":2454,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was originally granted on March 1, 2023 for the purchase of 44,000 shares of common stock. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2024, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":26130,"derivative":{"exercise_price":25.01,"expiration_date":"2033-03-01","underlying":"Common stock","underlying_shares":2454},"source":{"system":"sec-edgar","filing":"0001439222-25-000118","document":"wk-form4_1763068136.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922225000118/wk-form4_1763068136.xml","form_type":"4"}},{"id":1000431,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2025-11-13T21:08:59.000Z","date":"2025-11-11","kind":"sale","planned":true,"acquired":false,"shares":2454,"price":43.78,"value":107436.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $43.77 to $43.88. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":61727,"source":{"system":"sec-edgar","filing":"0001439222-25-000118","document":"wk-form4_1763068136.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922225000118/wk-form4_1763068136.xml","form_type":"4"}},{"id":1000430,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2025-11-13T21:08:59.000Z","date":"2025-11-11","kind":"exercise","planned":true,"acquired":true,"shares":2454,"price":25.01,"value":61374.54,"ownership":{"direct":true},"balance_after":64181,"source":{"system":"sec-edgar","filing":"0001439222-25-000118","document":"wk-form4_1763068136.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922225000118/wk-form4_1763068136.xml","form_type":"4"}},{"id":1009696,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock options (right to buy)","published_at":"2025-11-03T21:10:51.000Z","date":"2025-10-30","kind":"exercise","planned":true,"acquired":false,"shares":200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was originally granted on March 1, 2023 for the purchase of 44,000 shares of common stock. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2024, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":28584,"derivative":{"exercise_price":25.01,"expiration_date":"2033-03-01","underlying":"Common stock","underlying_shares":200},"source":{"system":"sec-edgar","filing":"0001881190-25-000004","document":"wk-form4_1762204249.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000188119025000004/wk-form4_1762204249.xml","form_type":"4"}},{"id":1009695,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2025-11-03T21:10:51.000Z","date":"2025-10-30","kind":"sale","planned":true,"acquired":false,"shares":200,"price":43.81,"value":8762.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":61727,"source":{"system":"sec-edgar","filing":"0001881190-25-000004","document":"wk-form4_1762204249.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000188119025000004/wk-form4_1762204249.xml","form_type":"4"}},{"id":1009694,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2025-11-03T21:10:51.000Z","date":"2025-10-30","kind":"exercise","planned":true,"acquired":true,"shares":200,"price":25.01,"value":5002.0,"ownership":{"direct":true},"balance_after":61927,"source":{"system":"sec-edgar","filing":"0001881190-25-000004","document":"wk-form4_1762204249.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000188119025000004/wk-form4_1762204249.xml","form_type":"4"}},{"id":1012112,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock options (right to buy)","published_at":"2025-10-29T20:02:29.000Z","date":"2025-10-27","kind":"exercise","planned":true,"acquired":false,"shares":3302,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was originally granted on March 1, 2023 for the purchase of 44,000 shares of common stock. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2024, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":28784,"derivative":{"exercise_price":25.01,"expiration_date":"2033-03-01","underlying":"Common stock","underlying_shares":3302},"source":{"system":"sec-edgar","filing":"0001439222-25-000111","document":"wk-form4_1761768146.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922225000111/wk-form4_1761768146.xml","form_type":"4"}},{"id":1012111,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2025-10-29T20:02:29.000Z","date":"2025-10-27","kind":"sale","planned":true,"acquired":false,"shares":3302,"price":43.92,"value":145023.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $43.77 to $44.13. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":61727,"source":{"system":"sec-edgar","filing":"0001439222-25-000111","document":"wk-form4_1761768146.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922225000111/wk-form4_1761768146.xml","form_type":"4"}},{"id":1012110,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2025-10-29T20:02:29.000Z","date":"2025-10-27","kind":"exercise","planned":true,"acquired":true,"shares":3302,"price":25.01,"value":82583.02,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 456 shares purchased through the Company's employee stock purchase plan."}],"balance_after":65029,"source":{"system":"sec-edgar","filing":"0001439222-25-000111","document":"wk-form4_1761768146.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922225000111/wk-form4_1761768146.xml","form_type":"4"}},{"id":1088664,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock options (right to buy)","published_at":"2025-07-11T20:59:12.000Z","date":"2025-07-09","kind":"exercise","planned":true,"acquired":false,"shares":11914,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was originally granted on March 1, 2023 for the purchase of 44,000 shares of common stock. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2024, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":32086,"derivative":{"exercise_price":25.01,"expiration_date":"2033-03-01","underlying":"Common stock","underlying_shares":11914},"source":{"system":"sec-edgar","filing":"0001439222-25-000082","document":"wk-form4_1752267546.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922225000082/wk-form4_1752267546.xml","form_type":"4"}},{"id":1088663,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2025-07-11T20:59:12.000Z","date":"2025-07-09","kind":"sale","planned":true,"acquired":false,"shares":847,"price":38.76,"value":32829.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $38.55 to $38.87. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":61271,"source":{"system":"sec-edgar","filing":"0001439222-25-000082","document":"wk-form4_1752267546.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922225000082/wk-form4_1752267546.xml","form_type":"4"}},{"id":1088662,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2025-07-11T20:59:12.000Z","date":"2025-07-09","kind":"sale","planned":true,"acquired":false,"shares":11067,"price":37.93,"value":419771.31,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $37.52 to $38.49. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":62118,"source":{"system":"sec-edgar","filing":"0001439222-25-000082","document":"wk-form4_1752267546.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922225000082/wk-form4_1752267546.xml","form_type":"4"}},{"id":1088661,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2025-07-11T20:59:12.000Z","date":"2025-07-09","kind":"exercise","planned":true,"acquired":true,"shares":11914,"price":25.01,"value":297969.14,"ownership":{"direct":true},"balance_after":73185,"source":{"system":"sec-edgar","filing":"0001439222-25-000082","document":"wk-form4_1752267546.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922225000082/wk-form4_1752267546.xml","form_type":"4"}},{"id":1092743,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted stock units","published_at":"2025-07-03T20:01:30.000Z","date":"2025-07-01","kind":"exercise","planned":true,"acquired":false,"shares":8374,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on July 1, 2023. Beginning on July 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on July 1, 2023. Beginning on July 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":8375,"derivative":{"underlying":"Common stock","underlying_shares":8374},"source":{"system":"sec-edgar","filing":"0001439222-25-000073","document":"wk-form4_1751572884.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922225000073/wk-form4_1751572884.xml","form_type":"4"}},{"id":1092742,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2025-07-03T20:01:30.000Z","date":"2025-07-01","kind":"sale","planned":true,"acquired":false,"shares":4091,"price":34.17,"value":139789.47,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated July 1, 2023."}],"balance_after":61271,"source":{"system":"sec-edgar","filing":"0001439222-25-000073","document":"wk-form4_1751572884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922225000073/wk-form4_1751572884.xml","form_type":"4"}},{"id":1092741,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2025-07-03T20:01:30.000Z","date":"2025-07-01","kind":"exercise","planned":true,"acquired":true,"shares":8374,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":65362,"source":{"system":"sec-edgar","filing":"0001439222-25-000073","document":"wk-form4_1751572884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922225000073/wk-form4_1751572884.xml","form_type":"4"}},{"id":1095612,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-02T20:43:25.000Z","date":"2025-07-01","kind":"grant","planned":false,"acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full upon the earlier to occur of (i) July 1, 2026 or (ii) the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer."}],"balance_after":21000,"derivative":{"exercise_price":14.47,"expiration_date":"2035-07-01","underlying":"Common Stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0000950170-25-093099","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000095017025093099/ownership.xml","form_type":"4"}},{"id":1101149,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Performance share units","published_at":"2025-06-26T21:25:32.000Z","date":"2025-06-24","kind":"exercise","planned":true,"acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each performance share unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The PSUs were granted on March 1, 2023. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified research milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified regulatory milestone. The performance criteria for the specified research milestone was determined to have been met on June 24, 2025, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The PSUs were granted on March 1, 2023. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified research milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified regulatory milestone. The performance criteria for the specified research milestone was determined to have been met on June 24, 2025, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":6000,"derivative":{"underlying":"Common stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001439222-25-000069","document":"wk-form4_1750973125.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922225000069/wk-form4_1750973125.xml","form_type":"4"}},{"id":1101148,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2025-06-26T21:25:32.000Z","date":"2025-06-24","kind":"sale","planned":true,"acquired":false,"shares":2909,"price":33.54,"value":97567.86,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's performance share unit agreement dated March 1, 2023."}],"balance_after":56988,"source":{"system":"sec-edgar","filing":"0001439222-25-000069","document":"wk-form4_1750973125.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922225000069/wk-form4_1750973125.xml","form_type":"4"}},{"id":1101147,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2025-06-26T21:25:32.000Z","date":"2025-06-24","kind":"exercise","planned":true,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":59897,"source":{"system":"sec-edgar","filing":"0001439222-25-000069","document":"wk-form4_1750973125.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922225000069/wk-form4_1750973125.xml","form_type":"4"}},{"id":1229523,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted stock units","published_at":"2025-03-04T21:08:38.000Z","date":"2025-03-01","kind":"exercise","planned":true,"acquired":false,"shares":5667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":11333,"derivative":{"underlying":"Common stock","underlying_shares":5667},"source":{"system":"sec-edgar","filing":"0001439222-25-000013","document":"wk-form4_1741122508.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922225000013/wk-form4_1741122508.xml","form_type":"4"}},{"id":1229522,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted stock units","published_at":"2025-03-04T21:08:38.000Z","date":"2025-03-01","kind":"exercise","planned":true,"acquired":false,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":4000,"derivative":{"underlying":"Common stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001439222-25-000013","document":"wk-form4_1741122508.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922225000013/wk-form4_1741122508.xml","form_type":"4"}},{"id":1229521,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted stock units","published_at":"2025-03-04T21:08:38.000Z","date":"2025-03-01","kind":"exercise","planned":true,"acquired":false,"shares":3833,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The restricted stock units were granted on  March 1, 2022. Beginning on March 1, 2023, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The restricted stock units were granted on  March 1, 2022. Beginning on March 1, 2023, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":3833},"source":{"system":"sec-edgar","filing":"0001439222-25-000013","document":"wk-form4_1741122508.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922225000013/wk-form4_1741122508.xml","form_type":"4"}},{"id":1229520,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock options (right to buy)","published_at":"2025-03-04T21:08:38.000Z","date":"2025-03-01","kind":"grant","planned":true,"acquired":true,"shares":43500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option was granted on March 1, 2025. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2026, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":43500,"derivative":{"exercise_price":35.54,"expiration_date":"2035-03-01","underlying":"Common stock","underlying_shares":43500},"source":{"system":"sec-edgar","filing":"0001439222-25-000013","document":"wk-form4_1741122508.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922225000013/wk-form4_1741122508.xml","form_type":"4"}},{"id":1229519,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted stock units","published_at":"2025-03-04T21:08:38.000Z","date":"2025-03-01","kind":"grant","planned":true,"acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The restricted stock units were granted on March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The restricted stock units were granted on March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":12000,"derivative":{"underlying":"Common stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001439222-25-000013","document":"wk-form4_1741122508.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922225000013/wk-form4_1741122508.xml","form_type":"4"}},{"id":1229518,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2025-03-04T21:08:38.000Z","date":"2025-03-03","kind":"sale","planned":true,"acquired":false,"shares":1681,"price":35.54,"value":59742.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"hares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2024."}],"balance_after":53897,"source":{"system":"sec-edgar","filing":"0001439222-25-000013","document":"wk-form4_1741122508.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922225000013/wk-form4_1741122508.xml","form_type":"4"}},{"id":1229517,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2025-03-04T21:08:38.000Z","date":"2025-03-01","kind":"exercise","planned":true,"acquired":true,"shares":5667,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":55578,"source":{"system":"sec-edgar","filing":"0001439222-25-000013","document":"wk-form4_1741122508.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922225000013/wk-form4_1741122508.xml","form_type":"4"}},{"id":1229516,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2025-03-04T21:08:38.000Z","date":"2025-03-03","kind":"sale","planned":true,"acquired":false,"shares":1187,"price":35.54,"value":42185.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2023."}],"balance_after":49911,"source":{"system":"sec-edgar","filing":"0001439222-25-000013","document":"wk-form4_1741122508.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922225000013/wk-form4_1741122508.xml","form_type":"4"}},{"id":1229515,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2025-03-04T21:08:38.000Z","date":"2025-03-01","kind":"exercise","planned":true,"acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":51098,"source":{"system":"sec-edgar","filing":"0001439222-25-000013","document":"wk-form4_1741122508.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922225000013/wk-form4_1741122508.xml","form_type":"4"}},{"id":1229514,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2025-03-04T21:08:38.000Z","date":"2025-03-03","kind":"sale","planned":true,"acquired":false,"shares":1137,"price":35.54,"value":40408.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2022."}],"balance_after":47098,"source":{"system":"sec-edgar","filing":"0001439222-25-000013","document":"wk-form4_1741122508.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922225000013/wk-form4_1741122508.xml","form_type":"4"}},{"id":1229513,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2025-03-04T21:08:38.000Z","date":"2025-03-01","kind":"exercise","planned":true,"acquired":true,"shares":3833,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 666 shares purchased through the Company's employee stock purchase plan."}],"balance_after":48235,"source":{"system":"sec-edgar","filing":"0001439222-25-000013","document":"wk-form4_1741122508.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922225000013/wk-form4_1741122508.xml","form_type":"4"}},{"id":1460422,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted stock units","published_at":"2024-07-03T20:30:08.000Z","date":"2024-07-01","kind":"exercise","planned":true,"acquired":false,"shares":8375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on July 1, 2023. Beginning on July 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on July 1, 2023. Beginning on July 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":16749,"derivative":{"underlying":"Common stock","underlying_shares":8375},"source":{"system":"sec-edgar","filing":"0001439222-24-000111","document":"wk-form4_1720038596.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922224000111/wk-form4_1720038596.xml","form_type":"4"}},{"id":1460421,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2024-07-03T20:30:08.000Z","date":"2024-07-01","kind":"sale","planned":true,"acquired":false,"shares":3705,"price":43.85,"value":162464.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated July 1, 2023."}],"balance_after":43736,"source":{"system":"sec-edgar","filing":"0001439222-24-000111","document":"wk-form4_1720038596.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922224000111/wk-form4_1720038596.xml","form_type":"4"}},{"id":1460420,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2024-07-03T20:30:08.000Z","date":"2024-07-01","kind":"exercise","planned":true,"acquired":true,"shares":8375,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":47441,"source":{"system":"sec-edgar","filing":"0001439222-24-000111","document":"wk-form4_1720038596.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922224000111/wk-form4_1720038596.xml","form_type":"4"}},{"id":1467346,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-28T20:25:36.000Z","date":"2024-06-26","kind":"grant","planned":false,"acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full upon the earlier to occur of (i) June 26, 2025 or (ii) the Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board."}],"balance_after":21000,"derivative":{"exercise_price":12.31,"expiration_date":"2034-06-26","underlying":"Common Stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0000950170-24-079084","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000095017024079084/ownership.xml","form_type":"4"}},{"id":1597521,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted stock units","published_at":"2024-03-05T21:20:43.000Z","date":"2024-03-01","kind":"exercise","planned":true,"acquired":false,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":8000,"derivative":{"underlying":"Common stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001439222-24-000054","document":"wk-form4_1709673617.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922224000054/wk-form4_1709673617.xml","form_type":"4"}},{"id":1597520,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted stock units","published_at":"2024-03-05T21:20:43.000Z","date":"2024-03-01","kind":"exercise","planned":true,"acquired":false,"shares":3834,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The restricted stock units were granted on  March 1, 2022. Beginning on March 1, 2023, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The restricted stock units were granted on  March 1, 2022. Beginning on March 1, 2023, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":3833,"derivative":{"underlying":"Common stock","underlying_shares":3834},"source":{"system":"sec-edgar","filing":"0001439222-24-000054","document":"wk-form4_1709673617.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922224000054/wk-form4_1709673617.xml","form_type":"4"}},{"id":1597519,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock options (right to buy)","published_at":"2024-03-05T21:20:43.000Z","date":"2024-03-01","kind":"grant","planned":true,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on March 1, 2024. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2025, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":60000,"derivative":{"exercise_price":32.27,"expiration_date":"2034-03-01","underlying":"Common stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001439222-24-000054","document":"wk-form4_1709673617.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922224000054/wk-form4_1709673617.xml","form_type":"4"}},{"id":1597518,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted stock units","published_at":"2024-03-05T21:20:43.000Z","date":"2024-03-01","kind":"grant","planned":true,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":17000,"derivative":{"underlying":"Common stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001439222-24-000054","document":"wk-form4_1709673617.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922224000054/wk-form4_1709673617.xml","form_type":"4"}},{"id":1597517,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2024-03-05T21:20:43.000Z","date":"2024-03-05","kind":"sale","planned":true,"acquired":false,"shares":1349,"price":32.57,"value":43936.93,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2023."}],"balance_after":39066,"source":{"system":"sec-edgar","filing":"0001439222-24-000054","document":"wk-form4_1709673617.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922224000054/wk-form4_1709673617.xml","form_type":"4"}},{"id":1597516,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2024-03-05T21:20:43.000Z","date":"2024-03-01","kind":"exercise","planned":true,"acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":40415,"source":{"system":"sec-edgar","filing":"0001439222-24-000054","document":"wk-form4_1709673617.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922224000054/wk-form4_1709673617.xml","form_type":"4"}},{"id":1597515,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2024-03-05T21:20:43.000Z","date":"2024-03-05","kind":"sale","planned":true,"acquired":false,"shares":1293,"price":32.57,"value":42113.01,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2022."}],"balance_after":36415,"source":{"system":"sec-edgar","filing":"0001439222-24-000054","document":"wk-form4_1709673617.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922224000054/wk-form4_1709673617.xml","form_type":"4"}},{"id":1597514,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2024-03-05T21:20:43.000Z","date":"2024-03-01","kind":"exercise","planned":true,"acquired":true,"shares":3834,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 2,587 shares purchased through the Company's employee stock purchase plan."}],"balance_after":37708,"source":{"system":"sec-edgar","filing":"0001439222-24-000054","document":"wk-form4_1709673617.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922224000054/wk-form4_1709673617.xml","form_type":"4"}},{"id":1643494,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted stock units","published_at":"2024-02-14T22:53:39.000Z","date":"2024-02-12","kind":"exercise","planned":true,"acquired":false,"shares":2162,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":2162},"source":{"system":"sec-edgar","filing":"0001439222-24-000030","document":"wk-form4_1707951190.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922224000030/wk-form4_1707951190.xml","form_type":"4"}},{"id":1643493,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2024-02-14T22:53:39.000Z","date":"2024-02-14","kind":"sale","planned":true,"acquired":false,"shares":642,"price":25.14,"value":16139.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated February 10, 2021."}],"balance_after":33431,"source":{"system":"sec-edgar","filing":"0001439222-24-000030","document":"wk-form4_1707951190.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922224000030/wk-form4_1707951190.xml","form_type":"4"}},{"id":1643492,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2024-02-14T22:53:39.000Z","date":"2024-02-12","kind":"exercise","planned":true,"acquired":true,"shares":2162,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":34073,"source":{"system":"sec-edgar","filing":"0001439222-24-000030","document":"wk-form4_1707951190.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922224000030/wk-form4_1707951190.xml","form_type":"4"}},{"id":1672223,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Performance share units","published_at":"2024-01-24T21:24:24.000Z","date":"2024-01-20","kind":"exercise","planned":true,"acquired":false,"shares":5750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each performance share unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The PSUs were granted on March 1, 2022. The PSUs vest upon the achievement of a specified research milestone. The performance criteria for the specified research milestone was determined to have been met on January 20, 2024, resulting in the vesting of the PSUs. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The PSUs were granted on March 1, 2022. The PSUs vest upon the achievement of a specified research milestone. The performance criteria for the specified research milestone was determined to have been met on January 20, 2024, resulting in the vesting of the PSUs. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":5750},"source":{"system":"sec-edgar","filing":"0001439222-24-000020","document":"wk-form4_1706131453.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922224000020/wk-form4_1706131453.xml","form_type":"4"}},{"id":1672222,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2024-01-24T21:24:24.000Z","date":"2024-01-24","kind":"sale","planned":true,"acquired":false,"shares":1708,"price":21.64,"value":36961.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2022."}],"balance_after":31911,"source":{"system":"sec-edgar","filing":"0001439222-24-000020","document":"wk-form4_1706131453.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922224000020/wk-form4_1706131453.xml","form_type":"4"}},{"id":1672221,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2024-01-24T21:24:24.000Z","date":"2024-01-20","kind":"exercise","planned":true,"acquired":true,"shares":5750,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":33619,"source":{"system":"sec-edgar","filing":"0001439222-24-000020","document":"wk-form4_1706131453.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922224000020/wk-form4_1706131453.xml","form_type":"4"}},{"id":1682953,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Performance share units","published_at":"2024-01-09T21:22:09.000Z","date":"2024-01-05","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each performance share unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The PSUs were granted on September 1, 2021. The PSUs vest upon the achievement of a specified clinical milestone. The performance criteria for the specified clinical milestone was determined to have been met on January 5, 2024, resulting in the vesting of the PSUs. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The PSUs were granted on September 1, 2021. The PSUs vest upon the achievement of a specified clinical milestone. The performance criteria for the specified clinical milestone was determined to have been met on January 5, 2024, resulting in the vesting of the PSUs. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001439222-24-000004","document":"wk-form4_1704835314.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922224000004/wk-form4_1704835314.xml","form_type":"4"}},{"id":1682952,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2024-01-09T21:22:09.000Z","date":"2024-01-09","kind":"sale","planned":true,"acquired":false,"shares":1789,"price":22.99,"value":41129.11,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated September 1, 2021."}],"balance_after":27869,"source":{"system":"sec-edgar","filing":"0001439222-24-000004","document":"wk-form4_1704835314.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922224000004/wk-form4_1704835314.xml","form_type":"4"}},{"id":1682951,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2024-01-09T21:22:09.000Z","date":"2024-01-05","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 499 shares purchased through the Company's employee stock purchase plan."}],"balance_after":29658,"source":{"system":"sec-edgar","filing":"0001439222-24-000004","document":"wk-form4_1704835314.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922224000004/wk-form4_1704835314.xml","form_type":"4"}},{"id":1774045,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-09-25T20:35:04.000Z","date":"2023-09-21","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in 36 equal monthly installments, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":40000,"derivative":{"exercise_price":15.74,"expiration_date":"2033-09-21","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000950170-23-049704","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000095017023049704/ownership.xml","form_type":"4"}},{"id":1834161,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted stock units","published_at":"2023-07-06T20:04:26.000Z","date":"2023-07-01","kind":"grant","planned":false,"acquired":true,"shares":25124,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on July 1, 2023. Beginning on July 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on July 1, 2023. Beginning on July 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":25124,"derivative":{"underlying":"Common stock","underlying_shares":25124},"source":{"system":"sec-edgar","filing":"0001439222-23-000111","document":"wk-form4_1688673850.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922223000111/wk-form4_1688673850.xml","form_type":"4"}},{"id":1841248,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Performance share units","published_at":"2023-06-30T20:06:33.000Z","date":"2023-06-28","kind":"exercise","planned":true,"acquired":false,"shares":5750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each performance share unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The PSUs vest as to 50% of the underlying shares upon the achievement of a specified clinical milestone and as to 50% of the underlying shares upon the achievement of a specified research milestone. The performance criteria for the specified clinical milestone was determined to have been met on June 28, 2023, resulting in the vesting of the PSUs as to 50% of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The PSUs vest as to 50% of the underlying shares upon the achievement of a specified clinical milestone and as to 50% of the underlying shares upon the achievement of a specified research milestone. The performance criteria for the specified clinical milestone was determined to have been met on June 28, 2023, resulting in the vesting of the PSUs as to 50% of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":5750,"derivative":{"underlying":"Common stock","underlying_shares":5750},"source":{"system":"sec-edgar","filing":"0001439222-23-000105","document":"wk-form4_1688155583.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922223000105/wk-form4_1688155583.xml","form_type":"4"}},{"id":1841247,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2023-06-30T20:06:33.000Z","date":"2023-06-30","kind":"sale","planned":true,"acquired":false,"shares":1707,"price":28.36,"value":48410.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units."}],"balance_after":24159,"source":{"system":"sec-edgar","filing":"0001439222-23-000105","document":"wk-form4_1688155583.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922223000105/wk-form4_1688155583.xml","form_type":"4"}},{"id":1841246,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2023-06-30T20:06:33.000Z","date":"2023-06-28","kind":"exercise","planned":true,"acquired":true,"shares":5750,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":25866,"source":{"system":"sec-edgar","filing":"0001439222-23-000105","document":"wk-form4_1688155583.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922223000105/wk-form4_1688155583.xml","form_type":"4"}},{"id":1974735,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted stock units","published_at":"2023-03-03T21:05:37.000Z","date":"2023-03-01","kind":"exercise","acquired":false,"shares":3833,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The restricted stock units were granted on  March 1, 2022. Beginning on March 1, 2023, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The restricted stock units were granted on  March 1, 2022. Beginning on March 1, 2023, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":7667,"derivative":{"underlying":"Common stock","underlying_shares":3833},"source":{"system":"sec-edgar","filing":"0001439222-23-000047","document":"wf-form4_167787751050589.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922223000047/wf-form4_167787751050589.xml","form_type":"4"}},{"id":1974734,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock options (right to buy)","published_at":"2023-03-03T21:05:37.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on March 1, 2023. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2024, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":44000,"derivative":{"exercise_price":25.01,"expiration_date":"2033-03-01","underlying":"Common stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0001439222-23-000047","document":"wf-form4_167787751050589.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922223000047/wf-form4_167787751050589.xml","form_type":"4"}},{"id":1974733,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted stock units","published_at":"2023-03-03T21:05:37.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on  March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on  March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":12000,"derivative":{"underlying":"Common stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001439222-23-000047","document":"wf-form4_167787751050589.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922223000047/wf-form4_167787751050589.xml","form_type":"4"}},{"id":1974732,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2023-03-03T21:05:37.000Z","date":"2023-03-03","kind":"tax_withholding","acquired":false,"shares":1134,"price":25.02,"value":28372.68,"ownership":{"direct":true},"balance_after":20116,"source":{"system":"sec-edgar","filing":"0001439222-23-000047","document":"wf-form4_167787751050589.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922223000047/wf-form4_167787751050589.xml","form_type":"4"}},{"id":1974731,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2023-03-03T21:05:37.000Z","date":"2023-03-01","kind":"exercise","acquired":true,"shares":3833,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 408 shares purchased through the Company's employee stock purchase plan."}],"balance_after":21250,"source":{"system":"sec-edgar","filing":"0001439222-23-000047","document":"wf-form4_167787751050589.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922223000047/wf-form4_167787751050589.xml","form_type":"4"}},{"id":2016930,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted stock units","published_at":"2023-02-14T21:07:23.000Z","date":"2023-02-10","kind":"exercise","acquired":false,"shares":2162,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":2162,"derivative":{"underlying":"Common stock","underlying_shares":2162},"source":{"system":"sec-edgar","filing":"0001439222-23-000017","document":"wf-form4_167640880440163.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922223000017/wf-form4_167640880440163.xml","form_type":"4"}},{"id":2016929,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2023-02-14T21:07:23.000Z","date":"2023-02-14","kind":"tax_withholding","acquired":false,"shares":758,"price":28.44,"value":21557.52,"ownership":{"direct":true},"balance_after":17009,"source":{"system":"sec-edgar","filing":"0001439222-23-000017","document":"wf-form4_167640880440163.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922223000017/wf-form4_167640880440163.xml","form_type":"4"}},{"id":2016928,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2023-02-14T21:07:23.000Z","date":"2023-02-10","kind":"exercise","acquired":true,"shares":2162,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":17767,"source":{"system":"sec-edgar","filing":"0001439222-23-000017","document":"wf-form4_167640880440163.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922223000017/wf-form4_167640880440163.xml","form_type":"4"}},{"id":2075595,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted stock units","published_at":"2022-12-28T21:05:04.000Z","date":"2022-12-23","kind":"exercise","acquired":false,"shares":9375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on December 23, 2020. The shares underlying the restricted stock units will vest in full on December 23, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on December 23, 2020. The shares underlying the restricted stock units will vest in full on December 23, 2022."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":9375},"source":{"system":"sec-edgar","filing":"0001439222-22-000104","document":"wf-form4_167226148971361.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922222000104/wf-form4_167226148971361.xml","form_type":"4"}},{"id":2075594,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2022-12-28T21:05:04.000Z","date":"2022-12-28","kind":"tax_withholding","acquired":false,"shares":2783,"price":28.48,"value":79259.84,"ownership":{"direct":true},"balance_after":15605,"source":{"system":"sec-edgar","filing":"0001439222-22-000104","document":"wf-form4_167226148971361.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922222000104/wf-form4_167226148971361.xml","form_type":"4"}},{"id":2075593,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2022-12-28T21:05:04.000Z","date":"2022-12-23","kind":"exercise","acquired":true,"shares":9375,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":18388,"source":{"system":"sec-edgar","filing":"0001439222-22-000104","document":"wf-form4_167226148971361.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922222000104/wf-form4_167226148971361.xml","form_type":"4"}},{"id":2094693,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted stock units","published_at":"2022-12-06T21:14:19.000Z","date":"2022-12-02","kind":"exercise","acquired":false,"shares":833,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on December 2, 2019. Beginning on December 2, 2020, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on December 2, 2019. Beginning on December 2, 2020, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":833},"source":{"system":"sec-edgar","filing":"0001439222-22-000101","document":"wf-form4_167036124284100.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922222000101/wf-form4_167036124284100.xml","form_type":"4"}},{"id":2094692,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2022-12-06T21:14:19.000Z","date":"2022-12-06","kind":"tax_withholding","acquired":false,"shares":248,"price":28.83,"value":7149.84,"ownership":{"direct":true},"balance_after":9013,"source":{"system":"sec-edgar","filing":"0001439222-22-000101","document":"wf-form4_167036124284100.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922222000101/wf-form4_167036124284100.xml","form_type":"4"}},{"id":2094691,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2022-12-06T21:14:19.000Z","date":"2022-12-02","kind":"exercise","acquired":true,"shares":833,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 660 shares purchased through the Company's employee stock purchase plan."}],"balance_after":9261,"source":{"system":"sec-edgar","filing":"0001439222-22-000101","document":"wf-form4_167036124284100.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922222000101/wf-form4_167036124284100.xml","form_type":"4"}},{"id":2355429,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock options (right to buy)","published_at":"2022-03-03T21:11:12.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":41000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on March 1, 2022. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":41000,"derivative":{"exercise_price":32.2,"expiration_date":"2032-03-01","underlying":"Common stock","underlying_shares":41000},"source":{"system":"sec-edgar","filing":"0001439222-22-000029","document":"wf-form4_164634182660786.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922222000029/wf-form4_164634182660786.xml","form_type":"4"}},{"id":2355428,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted stock units","published_at":"2022-03-03T21:11:12.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":11500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on  March 1, 2022. Beginning on March 1, 2023, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on  March 1, 2022. Beginning on March 1, 2023, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":11500,"derivative":{"underlying":"Common stock","underlying_shares":11500},"source":{"system":"sec-edgar","filing":"0001439222-22-000029","document":"wf-form4_164634182660786.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922222000029/wf-form4_164634182660786.xml","form_type":"4"}},{"id":2379071,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Performance share units","published_at":"2022-02-23T21:12:00.000Z","date":"2022-02-18","kind":"exercise","acquired":false,"shares":3271,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance share unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The PSUs vest as to one-third of the underlying shares of common stock, upon the achievement of each of three specified research, regulatory and commercial milestones, subject to continued service. The performance criteria for the specified regulatory milestone was determined to have been met on February 18, 2022, resulting in the vesting of the PSUs as to one-third of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The PSUs vest as to one-third of the underlying shares of common stock, upon the achievement of each of three specified research, regulatory and commercial milestones, subject to continued service. The performance criteria for the specified regulatory milestone was determined to have been met on February 18, 2022, resulting in the vesting of the PSUs as to one-third of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":3272,"derivative":{"underlying":"Common stock","underlying_shares":3271},"source":{"system":"sec-edgar","filing":"0001439222-22-000021","document":"wf-form4_164565070684880.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922222000021/wf-form4_164565070684880.xml","form_type":"4"}},{"id":2379070,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2022-02-23T21:12:00.000Z","date":"2022-02-22","kind":"tax_withholding","acquired":false,"shares":955,"price":29.08,"value":27771.4,"ownership":{"direct":true},"balance_after":7768,"source":{"system":"sec-edgar","filing":"0001439222-22-000021","document":"wf-form4_164565070684880.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922222000021/wf-form4_164565070684880.xml","form_type":"4"}}],"next_cursor":"2022-02-23T21:12:00.000000Z,2379070"}